In order to quickly and simultaneously obtain the chemical profiles and control the quality of the root of Polygonum multiflorum Thumb. and its processed form, a rapid qualitative and quantitative method, using ultra-high-performance liquid chromatography coupled with electrospray ionization-linear ion trap-Orbitrap hybrid mass spectrometry (UHPLC-LTQ-Orbitrap MSn) has been developed. The analysis was performed within 10 min on an AcQuity UPLC™ BEH C18 column with a gradient elution of 0.1% formic acid-acetonitrile at flow rate of 400 μL/min. According to the fragmentation mechanism and high resolution MSn data, a diagnostic ion searching strategy was used for rapid and tentative identification of main phenolic components and 23 compounds were simultaneously identified or tentatively characterized. The difference in chemical profiles between P. multiflorum and its processed preparation were observed by comparing the ions abundances of main constituents in the MS spectra and significant changes of eight metabolite biomarkers were detected in the P. multiflorum samples and their preparations. In addition, four of the representative phenols, namely gallic acid, trans-2,3,5,4′-tetra-hydroxystilbene-2-O-β-d-glucopyranoside, emodin and emodin-8-O-β-d-glucopyranoside were quantified by the validated UHPLC-MS/MS method. These phenols are considered to be major bioactive constituents in P. multiflorum, and are generally regarded as the index for quality assessment of this herb. The method was successfully used to quantify 10 batches of P. multiflorum and 10 batches of processed P.multiflorum. The results demonstrated that the method is simple, rapid, and suitable for the discrimination and quality control of this traditional Chinese herb.
As a critical hub between extracellular danger signals and intracellular inflammation, the P2X7 receptor centrally drives synovitis and joint destruction in rheumatoid arthritis, making it an attractive therapeutic target. This study reported the first-in-human data for EVT401, an orally administered P2X7 receptor antagonist. A phase I trial was conducted in healthy Chinese participants aged 18 to 50 years, encompassing a single ascending dose study (40-1920 mg), a food-effect study (960 mg), and a multiple ascending dose study (480 mg-960 mg). This randomized, double-blind, placebo-controlled trial evaluated safety, tolerability, and pharmacokinetic characteristics as primary outcomes. Exploratory outcomes assessed the pharmacodynamic effects of EVT401 on cytokines and immune cells. A total of 101 participants were enrolled in the trial. Only a few mild, transient adverse events were reported during the trial, and no serious adverse events were observed. The pharmacokinetic data obtained from each study were consistent, with Tmax ranging from 0.5 to 2.75 h and mean half-lives from 12.7 to 28.3 h. Dose-exposure analysis demonstrated that EVT401 had nonlinear pharmacokinetic characteristics. The food effect study showed that a high-fat meal increased the absorption and systemic exposure of EVT401. Exploratory pharmacodynamic results suggested that EVT401 exhibited an anti-inflammatory trend by upregulating regulatory T cells and suppressing helper T cells. The first-in-human data for EVT401 have demonstrated a favorable safety profile and encouraging pharmacodynamic properties, providing strong support for its further clinical development. This trial has been registered with the Chinese Clinical Trial Registry (ChiCTR2600126139, ChiCTR2600125998).
To compare the clinical efficacy and safety of biological disease-modifying antirheumatic drugs (DMARDs) and Janus kinase(JAK) inhibitors in patients with